Pfizer Inc. (NYSE:PFE) Shares Sold by Mach 1 Financial Group LLC

Mach 1 Financial Group LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 5.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 31,234 shares of the biopharmaceutical company’s stock after selling 1,755 shares during the quarter. Mach 1 Financial Group LLC’s holdings in Pfizer were worth $899,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its stake in Pfizer by 10.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after purchasing an additional 9,393,992 shares in the last quarter. Morgan Stanley lifted its stake in Pfizer by 0.4% in the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after purchasing an additional 348,628 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Pfizer by 9.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock worth $1,997,083,000 after purchasing an additional 5,185,453 shares in the last quarter. Invesco Ltd. lifted its stake in Pfizer by 30.9% in the 3rd quarter. Invesco Ltd. now owns 24,054,896 shares of the biopharmaceutical company’s stock worth $797,901,000 after purchasing an additional 5,678,004 shares in the last quarter. Finally, California Public Employees Retirement System lifted its stake in Pfizer by 0.6% in the 3rd quarter. California Public Employees Retirement System now owns 18,380,833 shares of the biopharmaceutical company’s stock worth $609,692,000 after purchasing an additional 101,256 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PFE has been the topic of a number of research reports. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Trading Down 0.1 %

NYSE PFE traded down $0.03 on Tuesday, reaching $25.61. The stock had a trading volume of 37,889,007 shares, compared to its average volume of 41,962,758. The firm has a market capitalization of $145.02 billion, a price-to-earnings ratio of 71.14, a P/E/G ratio of 1.14 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $40.37. The stock has a fifty day moving average price of $26.88 and a two-hundred day moving average price of $28.26.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.14 earnings per share. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.56%. Pfizer’s dividend payout ratio (DPR) is 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.